Home > Insider Trading > Filing (0001209191-23-002190)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1761612	Bicycle Therapeutics Plc	BCYC	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1618273	Lee Kalowski	C/O Bicycle Therapeutics Plc Blocks A &Amp; B, Portway Building Cambridge X0 CB21 6GS	President And Cfo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Acquisiton	2023-01-03	17,500	$0.00	32,500	No	4	A	Direct
Ordinary Shares	Disposition	2023-01-03	1,815	$29.06	30,685	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Employee Stock Option (right to buy)	Acquisiton	2023-01-03	35,000	$0.00	35,000	$29.60

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
35,000		2033-01-03	No	4	A	Direct

Footnotes

Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 3, 2024 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter.
Each RSU represents a contingent right to receive one ordinary share.
Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.545 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
This option shall vest one-fourth (1/4) of the total number of shares underlying the option on January 3, 2024 and the remaining shares in 36 equal monthly installments thereafter.